Linked Life Data

20925941

Source:http://linkedlifedata.com/resource/pubmed/id/20925941

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2010-10-20
pubmed:abstractText
Cystic Fibrosis (CF) is a life-shortening genetic disease in which ~80% of deaths result from loss of lung function linked to inflammation due to chronic bacterial infection (principally Pseudomonas aeruginosa). Pulmonary exacerbations (intermittent episodes during which symptoms of lung infection increase and lung function decreases) can cause substantial resource utilization, morbidity, and irreversible loss of lung function. Intravenous antibiotic treatment to reduce exacerbation symptoms is standard management practice. However, no prospective studies have identified an optimal antibiotic treatment duration and this lack of objective data has been identified as an area of concern and interest.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1465-993X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
137
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations.
pubmed:affiliation
Case Western Reserve University School of Medicine, Cleveland, OH, USA. enigmaster@comcast.net
pubmed:publicationType
Journal Article, Comparative Study